Orthofix Announces US and European Full Market Launch of OSCAR PRO System for Removal of Cement During Complex Joint Revision Surgeries

Orthofix Medical, Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the U.S. and European full market launch of the OSCAR PRO Ultrasonic Arthroplasty Revision System.

Designed to reduce the challenges associated with revising failed cemented arthroplasties, the OSCAR PRO is an ultrasonic surgical system that aids in the removal of cement during complex joint revision surgeries.

“The OSCAR PRO system is a fourth-generation product from the OSCAR line that has been the gold standard in assisting with complex joint revision surgeries since 1990,” said Orthofix President of Global Orthopedics Paul Gonsalves. “The technology is well accepted and has been used successfully for decades in removing cement total joint arthroplasties and aiding cementless prosthesis removal. We are pleased to continue to bring new innovations to the market to assist surgeons in performing these often challenging procedures.”

This next-generation product brings a technology platform to the market that extends functionalities beyond the original OSCAR system. The design includes an enhanced user interface to enable a more efficient surgical experience and new data collection capabilities.

Over time, joint replacements may fail and need surgical revision. Removing the implant can be challenging due to the need to efficiently remove the cement adhering the device to the bone. Traditional techniques for cement removal have included the use of drills, burrs, curettes and osteotomes. Mechanical removal through these methods can be difficult and time-consuming. The OSCAR PRO system uses ultrasonic vibrations to soften the cement holding the implant in place. The system also contains tools that enable the surgeon to remove the softened cement using specially designed probes.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”